CanSinoBIO Announces Approval for its MCV4 Product Menhyciaa?? in China

TIANJIN, China, Jan. 8, 2022 /PRNewswire/ -- CanSino Biologics Inc. ("CanSinoBIO") (SSE: 688185, HKEX: 06185) announced that the National Medical Products Administration of China ("NMPA") granted approval for its ACYW135 Meningococcal Conjugate Vaccine (CRM197) ("MCV4", trade name: Menhyciaa??), making it the first of its kind to be authorized in China.Leveraging CanSinoBIO's industry-leading synthetic biotechnology and formulation technology platform, Menhyciaa??A covalently binds common pathogenic meningococcal serogroups A, C, W135 and Y to the carrier protein CRM197. Currently, Menhyciaa??A is the initial vaccine product containing these four serogroups in China. In December 2019, the NMPA had granted Menhyciaa??A priority review status, making it the first MCV4 to be included on the priority review list in China.The approval marks an important step in accelerating the development of China's meningococcal vaccine immunization strategy. Menhyciaa??A provides protection for a wide range of age groups, including for children aged 3 months to 3 years old (47 months), by inducing strong T cell immune responses and immunological memory for immunized children.Dr. Xuefeng YU, Chairman and CEO of CanSinoBIO, said, "We are committed to contributing to disease prevention and control in China through innovation. Menhyciaa??A provides a cutting-edge solution in the prevention of meningococcal disease, and we are pleased to contribute to the advancement of the prevention and control capabilities of meningococcal disease in China."Currently, meningitis remains a serious challenge to global public health management. The World Health Organization's "Defeating Meningitis by 2030" plan aims to eliminate bacterial meningitis epidemics and reduce vaccine-preventable bacterial meningitis cases by 50% and deaths by 70%1.
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Январь 2022    »